DOT1L Antibody

Product Discontinued

DOT1L Antibody Summary

• Immunogen: Synthetic peptide C-SFSGVAGGTVGGN, representing the C-Terminus of the human protein according to NP_115871.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: DOT1L
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Peptide ELISA 1:32000
• Application Notes: Peptide ELISA: antibody detection limit dilution 1:32,000. Western Blot: Preliminary experiments gave no signal but low background in Human Kidney and Testis lysates at up to 1 ug/ml (Whole cell RIPA lysates not nuclear lysates). We would appreciate any feedback from people in the field - have any results been reported with other antibodies/lysates? Immunohistochemistry: Preliminary experiments in paraffin embedded Human kidney, shows cytoplasmic and nuclear staining of some epithelial cells in some renal tubules. Recommended concentration, 4 ug/ml.
• Control:

  DOT1L Overexpression Lysate

Reactivity Notes

Cross reacts with Mouse. Expected from sequence similarity: Rat and Dog.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: Tris (pH 7.3), 0.5% BSA
• Preservative: 0.02% Sodium Azide
• Concentration: 0.5 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for DOT1L Antibody

• DOT1L
• DOT1-like protein
• DOT1-like, histone H3 methyltransferase (S. cerevisiae)
• EC 2.1.1.43
• H3-K79-HMTase
• KIAA1814DKFZp586P1823
• KMT4
• KMT4H3 lysine-79 specific
• Lysine N-methyltransferase 4

Background

Dot1 (disruptor of telomeric silencing) is a class of histone methyltransferases that plays an indirect role in chromatin silencing by targeting a conserved lysine residue in the nucleosome core. Biochemical studies suggest that recombinant Dot1 proteins are active on recombinant nucleosomes, free of any modifications. This antibody was raised by a genetic immunization technique. Genetic immunization can be used to generate antibodies by directly delivering antigen-coding DNA into the animal, rather than injecting a protein or peptide (Tang et al. PubMed: 1545867; Chambers and Johnston PubMed 12910245; Barry and Johnston PubMed: 9234514). The animal's cells produce the protein, which stimulates the animal's immune system to produce antibodies against that particular protein. A vector coding for a partial fusion protein was used for genetic immunisation of a mouse and the resulting serum was tested in Western blot against an E.coli lysate containing that partial fusion protein. Genetic immunization offers enormous advantages over the traditional protein-based immunization method. DNA is faster, cheaper and easier to produce and can be produced by standard techniques readily amenable to automation. Furthermore, the antibodies generated by genetic immunization are usually of superior quality with regard to specificity, affinity and recognizing the native protein.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: DOT1L
• Entrez:
  • 84444(Human)
• Uniprot:
  • NP_115871.(Human)